SG11202112229UA - Cdk inhibitors - Google Patents

Cdk inhibitors

Info

Publication number
SG11202112229UA
SG11202112229UA SG11202112229UA SG11202112229UA SG11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA
Authority
SG
Singapore
Prior art keywords
cdk inhibitors
cdk
inhibitors
Prior art date
Application number
SG11202112229UA
Other languages
English (en)
Inventor
Zhilong Hu
Hu He
Fei Zhang
Xiaotian Zhu
Wenge Zhong
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of SG11202112229UA publication Critical patent/SG11202112229UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202112229UA 2019-05-05 2020-05-05 Cdk inhibitors SG11202112229UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085494 2019-05-05
PCT/CN2020/088585 WO2020224568A1 (en) 2019-05-05 2020-05-05 Cdk inhibitors

Publications (1)

Publication Number Publication Date
SG11202112229UA true SG11202112229UA (en) 2021-12-30

Family

ID=73051265

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112229UA SG11202112229UA (en) 2019-05-05 2020-05-05 Cdk inhibitors

Country Status (17)

Country Link
US (4) US20220296595A1 (de)
EP (2) EP3966213A4 (de)
JP (2) JP2022531687A (de)
KR (1) KR20220004755A (de)
CN (2) CN114364675A (de)
AU (2) AU2020269469A1 (de)
BR (1) BR112021022105A2 (de)
CA (1) CA3138973A1 (de)
CL (1) CL2021002903A1 (de)
CO (1) CO2021016504A2 (de)
EA (1) EA202193015A1 (de)
IL (1) IL287767A (de)
MA (1) MA55909A (de)
MX (1) MX2021013531A (de)
SG (1) SG11202112229UA (de)
TW (2) TW202108572A (de)
WO (2) WO2020224568A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020500A (zh) 2017-12-22 2020-12-01 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的氨基吡啶衍生物
AU2020215684A1 (en) * 2019-01-29 2021-08-12 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
SG11202112229UA (en) * 2019-05-05 2021-12-30 Qilu Regor Therapeutics Inc Cdk inhibitors
CA3197985A1 (en) * 2020-11-20 2022-05-27 Qingsong Liu Dihydroisoquinolinone and isoindolinone derivatives and uses thereof
WO2023143482A1 (zh) * 2022-01-29 2023-08-03 上海辉启生物医药科技有限公司 2-氨基嘧啶类化合物或其盐及其制备方法和用途
US20230322792A1 (en) * 2022-04-08 2023-10-12 Biolexis Therapeutics, Inc. Cdk9 inhibitors
CN117645604A (zh) * 2022-09-05 2024-03-05 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
UY27487A1 (es) * 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
WO2008003766A2 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
SG10202004716RA (en) * 2014-07-24 2020-06-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
US9969719B2 (en) * 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
TWI736578B (zh) * 2016-02-06 2021-08-21 大陸商上海複尚慧創醫藥研究有限公司 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
MX2018012622A (es) * 2016-04-15 2019-08-29 Epizyme Inc Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
WO2018045957A1 (zh) * 2016-09-07 2018-03-15 江苏豪森药业集团有限公司 一种cdk4/6抑制剂及其制备方法和应用
TWI732083B (zh) * 2016-12-22 2021-07-01 大陸商貝達藥業股份有限公司 苯并咪唑衍生物、其藥物組合物及其應用
WO2018121766A1 (zh) * 2016-12-30 2018-07-05 上海医药集团股份有限公司 含氮稠杂环化合物、其制备方法、中间体、组合物和应用
CN108794452B (zh) * 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
CN109503573A (zh) * 2017-09-14 2019-03-22 昆明圣加南生物科技有限公司 2-取代苯胺基嘧啶衍生物及其用途
US10519136B2 (en) * 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
BR112020015405A2 (pt) * 2018-01-29 2020-12-08 Beta Pharma, Inc. Compostos de 2h-indazóis como inibidores cdk4 e cdk6, composições farmacêuticas que os compreendem, seus usos terapêuticos e métodos de preparação
SG11202112229UA (en) * 2019-05-05 2021-12-30 Qilu Regor Therapeutics Inc Cdk inhibitors

Also Published As

Publication number Publication date
KR20220004755A (ko) 2022-01-11
US20220296595A1 (en) 2022-09-22
EA202193015A1 (ru) 2022-03-17
WO2021226140A1 (en) 2021-11-11
IL287767A (en) 2022-01-01
CN115803327A (zh) 2023-03-14
CL2021002903A1 (es) 2022-07-08
JP2022531687A (ja) 2022-07-08
JP2023525005A (ja) 2023-06-14
EP4146647A1 (de) 2023-03-15
CA3138973A1 (en) 2020-11-12
MX2021013531A (es) 2022-02-11
BR112021022105A2 (pt) 2021-12-28
EP3966213A4 (de) 2023-04-19
CO2021016504A2 (es) 2022-01-17
US20240033264A1 (en) 2024-02-01
CN114364675A (zh) 2022-04-15
US20230174512A1 (en) 2023-06-08
US20240066031A1 (en) 2024-02-29
TW202108572A (zh) 2021-03-01
AU2021268648A1 (en) 2023-01-19
MA55909A (fr) 2022-03-16
EP3966213A1 (de) 2022-03-16
WO2020224568A1 (en) 2020-11-12
TW202144351A (zh) 2021-12-01
CN115803327B (zh) 2024-02-13
AU2020269469A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
IL290341A (en) prmt5 inhibitors that cooperate with mta
IL287767A (en) cdk inhibitors
EP3833355A4 (de) Prmt5-inhibitoren
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
ZA202106284B (en) Rad51 inhibitors
IL289914A (en) enzyme inhibitors
EP3817736A4 (de) Pikfyve-inhibitoren
EP3833668A4 (de) Prmt5-inhibitoren
IL289863A (en) enzyme inhibitors
IL276013A (en) pi4kiiibeta inhibitors
IL289783A (en) enzyme inhibitors
IL289778A (en) enzyme inhibitors
IL288306A (en) Combined treatments using cdk inhibitors
IL283309A (en) rip1 inhibitors
ZA202109573B (en) Prmt5 inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
EP3976797A4 (de) Anti-crispr-inhibitoren
EP3833667A4 (de) Prmt5-inhibitoren
IL280408A (en) CDK inhibitors and uses thereof
EP3768256A4 (de) Pan-tropische eingangsinhibitoren
GB201807845D0 (en) Kinase Inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201914388D0 (en) Kinase inhibitors